Restatement of previously issued financial statements: (Tables)

12 Months Ended

Dec. 31, 2012

Restatement of previously issued financial statements:

Schedule of effect on consolidated statement of Balance Sheet

Effect on Consolidated Balance Sheet:	December 31, 2011 As previously reported			Correction			December 31, 2011 Restated – note 2(a)
Assets
Current assets:
Cash and cash equivalents	$	70,298		$	(7,013	)	$	63,285
Short-term investments	15,379			(11,105		)	4,274
Accounts receivable	55,423			(4,501		)	50,922
Loan receivable	19,409			(19,409		)	—
Inventories	37,057			(31		)	37,026
Prepaid expenses	6,551			(89		)	6,462
Current portion of deferred income tax assets	6,447			(793		)	5,654
Other current assets	2,034			—			2,034
	212,598			(42,941		)	169,657
Long-term investments	8,369			17,938			26,307
Other assets	1,994			—			1,994
Property, plant and equipment	36,243			(835		)	35,408
Intangible assets	36,582			—			36,582
Deferred income tax assets	5,075			(5,075		)	—
Goodwill	55,814			—			55,814
	$	356,675		$	(30,913	)	$	325,762
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	55,807		$	(6,556	)	$	49,251
Deferred revenue	3,146			(2,668		)	478
Loan payable	—			19,409			19,409
Current portion of long-term debt	20,568			—			20,568
Current portion of warranty liability	12,978			(11,791		)	1,187
	92,499			(1,606		)	90,893
Warranty liability	11,253			(8,039		)	3,214
Long-term debt	65,577			—			65,577
Deferred revenue	10,327			(7,451		)	2,876
Deferred income tax liabilities	3,446			4,706			8,152
Other long-term liabilities	3,104			(644		)	2,460
	186,206			(13,034		)	173,172
Shareholders’ equity:
Share capital	459,866			—			459,866
Other equity instruments	6,112			—			6,112
Additional paid in capital	4,499			—			4,499
Accumulated deficit	(331,158		)	—			(331,158		)
Accumulated other comprehensive income	13,271			—			13,271
	152,590			—			152,590
Joint venture partners’ share of net assets of joint ventures	17,879			(17,879		)	—
	170,469			(17,879		)	152,590
	$	356,675		$	(30,913	)	$	325,762

Schedule of effect on consolidated statements of operations

	For the Nine months ended December 31, 2011
Effect on Consolidated Statements of Operations:	As previously reported			Correction			Restated — note 2(a)
Product revenue	$	189,682		$	(114,518	)	$	75,164
Parts revenue	26,677			(24,326		)	2,351
Service and other revenue	10,181			—			10,181
	226,540			(138,844		)	87,696
Cost of revenue and expenses:
Cost of product and parts revenue	145,930			(78,837		)	67,093
Research and development	43,294			(6,720		)	36,574
General and administrative	23,534			(796		)	22,738
Sales and marketing	24,961			(9,659		)	15,302
Foreign exchange loss (gain)	(2,036		)	(17		)	(2,053		)
Depreciation and amortization	6,280			(80		)	6,200
Bank charges, interest and other	1,206			(289		)	917
	243,169			(96,398		)	146,771
Loss before undernoted	(16,629		)	(42,446		)	(59,075		)
Income from investment accounted for by the equity method	1,500			12,958			14,458
Interest on long-term debt and amortization of discount	(2,998		)	—			(2,998		)
Interest and other income	958			(297		)	661
Loss before income taxes	(17,169		)	(29,785		)	(46,954		)
Income tax recovery (expense):
Current	(19,630		)	18,602			(1,028		)
Deferred	3,963			(1,775		)	2,188
	(15,667		)	16,827			1,160
Net loss for the period	$	(32,836	)	$	(12,958	)	$	(45,794	)
Net income (loss) attributed to:
Joint venture partners	12,958			(12,958		)	—
The Company	(45,794		)	—			(45,794		)
Loss per share:
Basic and diluted	$	(0.96	)	$	—		$	(0.96	)
Weighted average common shares outstanding:
Basic and diluted	47,933,348						47,933,348

	For the Year ended March 31, 2011
Effect on Consolidated Statements of Operations:	As previously reported			Correction			Restated — note 2(a)
Product revenue	$	110,475		$	(84,612	)	$	25,863
Parts revenue	29,459			(26,675		)	2,784
Service and other revenue	8,128			—			8,128
	148,062			(111,287		)	36,775
Cost of revenue and expenses:
Cost of product and parts revenue	90,982			(66,989		)	23,993
Research and development	34,663			(10,043		)	24,620
General and administrative	16,211			(1,181		)	15,030
Sales and marketing	21,660			(7,675		)	13,985
Foreign exchange loss (gain)	3,877			(588		)	3,289
Depreciation and amortization	3,455			(80		)	3,375
Bank charges, interest and other	665			(219		)	446
	171,513			(86,775		)	84,738
Loss before undernoted	(23,451		)	(24,512		)	(47,963		)
Income from investment accounted for by the equity method	842			7,785			8,627
Interest on long-term debt and amortization of discount	(3,323		)	—			(3,323		)
Interest and other income	1,222			(284		)	938
Loss before income taxes	(24,710		)	(17,011		)	(41,721		)
Income tax recovery (expense):
Current	(8,886		)	8,954			68
Deferred	(761		)	272			(489		)
	(9,647		)	9,226			(421		)
Net loss for the period	$	(34,357	)	$	(7,785	)	$	(42,142	)
Net income (loss) attributed to:
Joint venture partners	7,785			(7,785		)	—
The Company	(42,142		)	—			(42,142		)
Loss per share:
Basic and diluted	$	(1.00	)	$	—		$	(1.00	)
Weighted average common shares outstanding:
Basic and diluted	42,305,889						42,305,889

Schedule of effect on consolidated statement of comprehensive income (loss)

	For the Nine months ended December 31, 2011
Effect on Consolidated Statement Comprehensive  Income (Loss):	As previously reported			Correction			Restated — note 2(a)
Loss for the period	$	(32,836	)	$	(12,958	)	$	(45,794	)
Other comprehensive loss:
Cumulative translation adjustment	(12,370		)	—			(12,370		)
Comprehensive loss	$	(45,206	)	$	(12,958	)	$	(58,164	)
Comprehensive income (loss) attributable to:
Joint venture partners	12,958			(12,958		)	—
The Company	(58,164		)	—			(58,164		)

	For the Year ended March 31, 2011
Effect on Consolidated Statement Comprehensive Income (Loss):	As previously reported			Correction			Restated — note 2(a)
Loss for the period	$	(34,357	)	$	(7,785	)	$	(42,142	)
Other comprehensive income:
Cumulative translation adjustment	7,414			—			7,414
Comprehensive loss	$	(26,943	)	$	(7,785	)	$	(34,728	)
Comprehensive income (loss) attributable to:
Joint venture partners	7,785			(7,785		)	—
The Company	(34,728		)	—			(34,728		)

Schedule of effect on consolidated statement of cash flow

	For the Nine months ended December 31, 2011
Effect on Consolidated Statement of Cash Flow:	As previously reported			Correction			Restated — note 2(a)
Cash flows from operating activities:
Loss for the period	$	(32,836	)	$	(12,958	)	$	(45,794	)
Items not involving cash:
Depreciation and amortization	6,280			(80		)	6,200
Stock-based compensation expense	6,179			—			6,179
Deferred income tax expense (recovery)	(3,963		)	1,775			(2,188		)
Change in deferred lease inducements	(47		)	—			(47		)
Income from investment accounted for by the equity method	(1,500		)	(12,958		)	(14,458		)
Accretion of long-term debt	1,016			—			1,016
Other	654			—			654
Changes in non-cash operating working capital:
Accounts receivable	(18,581		)	3,983			(14,598		)
Inventories	(2,051		)	—			(2,051		)
Prepaid expenses	(4,639		)	(10		)	(4,649		)
Accounts payable and accrued liabilities	3,255			(4,112		)	(857		)
Deferred revenue	4,430			(2,869		)	1,561
Warranty liability	5,860			(3,109		)	2,751
	(35,943		)	(30,338		)	(66,281		)
Cash flows from investing activities:
Purchase of property, plant and equipment	(13,269		)	146			(13,123		)
Purchase of intangible assets	(123		)	—			(123		)
Sale of short-term investments, net	15,516			11,105			26,621
Advances on loan receivable	(29,816		)	29,816			—
Increase in loan payable	—			29,080			29,080
Repayment on loan receivable	24,013			(24,013		)	—
Repayment of loan payable	—			(23,840		)	(23,840		)
Acquisitions, net of acquired cash	(9,084		)	—			(9,084		)
Investment in equity interest	(955		)	—			(955		)
Dividends received from joint venture	—			10,000			10,000
	(13,718		)	32,294			18,576
Cash flows from financing activities:
Repayment on operating lines of credit	(3,240		)	—			(3,240		)
Repayment of short-term debt	(221		)	—			(221		)
Repayment of long-term debt	(53,057		)	—			(53,057		)
Issuance of subordinated debenture notes	34,345			—			34,345
Finance costs incurred	(1,392		)	—			(1,392		)
Proceeds from stock options exercised	1,816			—			1,816
Dividends paid to joint venture partner	(10,000		)	10,000			—
	(31,749		)	10,000			(21,749		)
Effect of foreign exchange on cash and cash equivalents	3,246			(2,040		)	1,206
Increase (decrease) in cash and cash equivalents	(78,164		)	9,916			(68,248		)
Cash and cash equivalents, beginning of period	148,462			(16,929		)	131,533
Cash and cash equivalents, end of period	$	70,298		$	(7,013	)	$	63,285

	For the Year ended March 31, 2011
Effect on Consolidated Statement of Cash Flow:	As previously reported			Correction			Restated — note 2(a)
Cash flows from operating activities:
Loss for the period	$	(34,357	)	$	(7,785	)	$	(42,142	)
Items not involving cash:
Depreciation and amortization	3,455			(80		)	3,375
Stock-based compensation expense	4,923			—			4,923
Deferred income tax expense (recovery)	761			(272		)	489
Change in deferred lease inducements	(58		)	—			(58		)
Income from investment accounted for by the equity method	(842		)	(7,785		)	(8,627		)
Accretion of long-term debt	1,992			—			1,992
Other	(344		)	509			165
Changes in non-cash operating working capital:
Accounts receivable	5,523			(1,604		)	3,919
Inventories	(1,927		)	—			(1,927		)
Prepaid expenses	(488		)	31			(457		)
Accounts payable and accrued liabilities	(2,831		)	2,958			127
Deferred revenue	3,058			(2,896		)	162
Warranty liability	(2,844		)	2,460			(384		)
	(23,979		)	(14,464		)	(38,443		)
Cash flows from investing activities:
Purchase of property, plant and equipment	(3,613		)	442			(3,171		)
Sale of short-term investments, net	3,376			—			3,376
Advances on loan receivable	(20,942		)	20,942			—
Increase in loan payable	—			18,961			18,961
Repayment on loan receivable	18,185			(18,185		)	—
Repayment of loan payable	—			(21,207		)	(21,207		)
Acquisitions, net of acquired cash	(13,016		)	—			(13,016		)
Investment in equity interest	(4,316		)	—			(4,316		)
Dividends received from joint venture	—			6,000			6,000
	(20,326		)	6,953			(13,373		)
Cash flows from financing activities:
Repayment of demand installment loan	(3,206		)	—			(3,206		)
Repayment of long-term debt	(117		)	—			(117		)
Proceeds from stock options exercised	3,298			—			3,298
Shares issued for cash	131,265			—			131,265
Share issuance costs	(6,069		)	—			(6,069		)
Dividends paid to joint venture partner	(6,000		)	6,000			—
	119,171			6,000			125,171
Effect of foreign exchange on cash and cash equivalents	3,116			1,042			4,158
Increase (decrease) in cash and cash equivalents	77,982			(469		)	77,513
Cash and cash equivalents, beginning of period	70,480			(16,460		)	54,020
Cash and cash equivalents, end of period	$	148,462		$	(16,929	)	$	131,533

Schedule of effect on segmented information

	December 31,  2011  As previously				December 31,  2011  Restated –
Effect on total assets allocated by segment:	reported		Correction		note 2(a)
Applied Technologies	$	165,192	$	4,706	$	169,898

Effect on long-lived assets information by	December 31,  2011  As previously					December 31,  2011  Restated –
geographic area:	reported		Correction			note 2(a)
Italy	$	94,889	$	10,712		$	105,601
Canada	27,006		(10,712		)	16,294

Effect on long-lived assets information by	December 31,  2012  As previously					December 31,  2012  Restated –
geographic area:	reported		Correction			note 2(a)
Italy	$	90,474	$	8,625		$	99,099
Canada	40,799		(11,092		)	29,707
Sweden	5,253		2,467			7,720